5:05 PM
 | 
Aug 06, 2013
 |  BC Extra  |  Financial News

Regeneron falls on 2Q13 miss

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) fell $16.49 to $254.50 on Tuesday after reporting 2Q13 earnings that missed the Street, despite announcing accelerated plans to seek a label expansion for ophthalmic drug Eylea aflibercept. The company reported 2Q13 GAAP diluted EPS of $0.79, up from $0.70 in 2Q12 but missing the Street's $0.88 estimate. Revenues in the quarter jumped 50% to $458 million but came in below the...

Read the full 319 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >